Cleavable Linker Protein Complex for Bispecific Antibody Production
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing bi-specific antibodies face challenges such as high manufacturing costs, low efficacy, and side effects, limiting their commercialization and mass production, with no leading technology reported for their production.
Innovation Solution
A protein complex comprising at least two polypeptides with antigen binding sites linked by a linker that includes a cleavable amino acid sequence, allowing for the production of bi-specific antibodies or antibody-like molecules targeting multiple antigens.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If conventional methods are used to produce bi-specific antibodies, then manufacturing costs are high and efficacy is low, but the production process remains complex and difficult to scale
Solution Approach 1:
The bi-specific antibody is divided into two separate monoclonal antibodies that are produced independently and then combined through a mixing process. This segmentation allows each antibody to be optimized and produced using established monoclonal antibody manufacturing processes, reducing overall production complexity and cost while maintaining the bi-specific functionality.
Solution Approach 2:
Two separate monoclonal antibodies are merged into a single bi-specific antibody product through a mixing process. This combining approach simplifies the production process compared to traditional fusion methods, as it allows the use of standardized monoclonal antibody manufacturing protocols for both components while achieving the desired multi-specific activity.
2Productivity
If conventional bi-specific antibody production methods are used, then mass production is difficult, but the efficacy and side effect profile remain unsatisfactory
Solution Approach 1:
The two monoclonal antibodies are prepared and purified separately in advance using well-established monoclonal antibody production protocols, ensuring high efficacy and proper folding. Only after these preliminary steps are completed are the antibodies combined in the final mixing process, which simplifies mass production while maintaining reliability.
Solution Approach 2:
The bi-specific antibody formation process is self-assembling through the mixing of two pre-prepared monoclonal antibodies, eliminating the need for complex in vivo or in vitro fusion procedures. This self-assembly mechanism enables straightforward scale-up to mass production while preserving the functional integrity and efficacy of the final product.
3Adaptability or versatility
If existing antibody platforms are used, then verification is still ongoing, but the technology is not yet ready for commercialization
Solution Approach 1:
The bi-specific antibody platform is designed to be universally applicable for targeting multiple antigens simultaneously. By using two separate monoclonal antibodies that can be independently engineered and produced, the platform achieves versatility in targeting different antigens while maintaining commercialization readiness through the use of standardized manufacturing processes.
Solution Approach 2:
The platform utilizes two separate, independently producible monoclonal antibodies that can be manufactured using established, cost-effective processes. This approach replaces the need for expensive and complex in vivo fusion methods, making the technology economically viable and ready for commercialization while maintaining the ability to target multiple antigens.
Data Source
AI summary
A protein complex including at least two monoclonal antibodies is provided. By using the protein complex, a system for simultaneously targeting at least two antigens is effectively constructed.